Squid Peptides Activate V1B Receptors for Stress Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current research on V1B receptors is limited, and there is a need for effective peptides that can regulate these receptors for the prevention or treatment of V1B receptor-related diseases.
Innovation Solution
The use of squid-derived peptides, specifically squidtocin and pro-sepiatocin, which are shown to activate the V1B receptor, offering a potential therapeutic approach for V1B receptor-related diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional research methods are used for V1B receptors, then limited research progress is achieved, but effective therapeutic peptides are not discovered
Solution Approach 1:
The patent applies parameter changes by shifting from conventional receptor research approaches to screening peptides based on amino acid sequence homology with known V1B receptor ligands. This parameter change in the research methodology enabled the discovery of squidtocin and pro-sepiatocin as effective V1B receptor activators, resolving the contradiction between research productivity and therapeutic reliability
2Reliability
If V1B receptor agonists are developed, then stress response and sociality functions are enhanced, but selectivity among receptor subtypes must be maintained
Solution Approach 1:
The patent applies local quality by designing peptides with specific amino acid sequences (Cys-Tyr-Phe-Arg-Asn-Cys-Pro-Ala-Gly-NH2 for squidtocin) that exhibit selective affinity for V1B receptors. The localized structural features and specific amino acid residues confer subtype selectivity, enabling the peptides to activate V1B receptors while maintaining discrimination from other vasopressin and oxytocin receptor subtypes
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Squidtocin and pro-sepiatocin have been confirmed to selectively activate the V1B receptor, which is involved in stress response and sociality, providing a novel avenue for treating V1B receptor-related diseases.
Implementation Method 1
When the V1B receptor is activated by binding to vasopressin, intracellular signaling mediated by a G protein occurs
Data Source
AI summary
The present invention relates to squid-derived peptides and uses thereof and, more specifically, to uses of squid-derived peptides squidtocin and pro-sepiatocin for prevention or treatment of V1B receptor-related diseases. It has been confirmed that the squidtocin and pro-sepiatocin according to the present invention have an effect of inducing activation of a V1B receptor which is a type of vasopressin receptor. The V1B receptor which is a type of vasopressin receptor is present in the anterior pituitary and in the hippocampal CA2 region, and it is known that the V1B receptor increases intracellular calcium concentration and is involved in response to stress and sociality. Accordingly, the squidtocin and the pro-sepiatocin according to the present invention can be used in various ways in the field of prevention, amelioration, or treatment of V1B receptor-related diseases.